



(51) International Patent Classification:

C12N 15/86 (2006.01) C07K 14/705 (2006.01)
A61K 48/00 (2006.01) A61P 27/02 (2006.01)

(21) International Application Number:

PCT/EP2022/064349

(22) International Filing Date:

25 May 2022 (25.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21305686.4 26 May 2021 (26.05.2021) EP

(71) Applicants: SPARINGVISION [FR/FR]; 5-7, avenue Percier, 75008 PARIS (FR). RUHR-UNIVERSITÄT BOCHUM [DE/DE]; Universitätsstraße 150, 44801 BOCHUM (DE). INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) [FR/FR]; 101, rue de Tolbiac, 75013 PARIS (FR). CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - [FR/FR]; 3, rue Michel Ange, 75016

PARIS (FR). SORBONNE UNIVERSITE [FR/FR]; 21 Rue de l'Ecole de Médecine, 75006 PARIS (FR).

(72) Inventors: DALKARA, Deniz; Inserm 968 Institut de la Vision, 17 rue Moreau, 75012 PARIS (FR). HERLITZE, Stephan; c/o RUHR-UNIVERSITÄT BOCHUM, Universitätsstraße 150, 44801 BOCHUM (DE). MÜCHER, Brix; RUHR-UNIVERSITÄT BOCHUM, Universitätsstraße 150, 44801 BOCHUM (DE). KHABOU, Hassen; 9 place Louis Aragon, 93160 NOISY LE GRAND (FR).

(74) Agent: PLASSERAUD IP; 66 rue de la Chaussée d'Antin, 75440 PARIS CEDEX 09 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: G-PROTEIN-GATED-K⁺ CHANNEL-MEDIATED ENHANCEMENTS IN LIGHT SENSITIVITY IN ROD-CONE DYSTROPHY (RCD)




FIG.1

(57) Abstract: The present invention concerns a new gene therapy approach to increase light-sensitivity in degenerating cones in advanced stages of rod-cone dystrophy (RCD) mediated by G-protein-gated-K⁺ channel (GIRK), in particular GIRK1 F137S, activated by G proteins recruited by cone opsin expressed in degenerating cones.

[Continued on next page]

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*